U.S. regulatory advisors recommended strengthening safety warnings on GlaxoSmithKline's asthma drug Serevent amid new reports of deaths among children taking the drug.
A Food and Drug Administration expert panel reviewed nine new adverse-event reports on children taking the inhaled treatment, including five deaths in about a year.
